Bavarian Nordic

AGM Information • Jan 6, 2010

Company Announcement

6 January 2010

Bavarian Nordic A/S – Report on the Results of the Extraordinary General Meeting, held 6 January 2010

An Extraordinary General Meeting of Bavarian Nordic A/S was held today following results: 6 January 2010 2010 with the

The General Assembly adopted the Board of Directors' proposal to amend:

• Article 5a of the Articles of Association (Authorization for Increase of the Company' Capital); and Company's Share
• Article 8 (Change of name of Change Stock Register).

Asger Aamund Chairman of the Board

Contact Anders Hedegaard, President & CEO CEO. Phone +45 23 20 30 64

Forward-looking statements

This announcement includes "forwardwhich are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forwardfuture events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subse except as required by law. -looking statements" that involve risks, uncertainties and other factors, many of -looking statements include statements concerning our plans, objectives, goals, looking subsequent events or circumstances after the date made, looking atements quent ing

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threaten in the three areas; biodefence, cancer and infectious diseases, and includes seven development programmes. Two programmes are ready for Phase III: IMVAMUNE®, a third with the US government, and PROSTVAC™, a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute. threatening diseases with a large unmet medical need. The company's pipeline is focused third-generation smallpox vaccine is being developed under a contract

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit www.bavarian d www.bavarian-nordic.com

Company Announcement no. Page 1 of 1 1 / 2010

Bavarian Nordic A/S Hejreskovvej 10A

DK-3490 Kvistgaard Denmark

3490 Kvistgaard Fax: +45 33 26 83 80

10A Tel: +45 33 26 83 83 www.bavarian-nordic.com

nordic.com CVR-no: 16 27 11 87